Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RIZATRIPTAN BENZOATE ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for RIZATRIPTAN BENZOATE ORALLY DISINTEGRATING TABLETS. RIZATRIPTAN BENZOATE orally disintegrating tablets, for oral use Initial U.S. Approval: 1998
Medication labelWhy this: Advisory · dailymed-prescription
Rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate orally disintegrating tablets are administered to treat any subsequent attacks. Rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)] . Rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate orally disintegrating tablets have not been established for cluster headache.
- generic_name
- rizatriptan benzoate
- product_names
- Rizatriptan Benzoate
- ndc
- 70518-4362, 65862-626, 70518-4362-0
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en